Page last updated: 2024-11-05

2,3,3-triphenylacrylonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3,3-triphenylacrylonitrile: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID22743
CHEMBL ID305168
CHEBI ID34217
SCHEMBL ID1343904
MeSH IDM0121677

Synonyms (48)

Synonym
alpha-(diphenylmethylene)benzeneacetic acid
nsc 42900
brn 1980289
alpha,beta-diphenylcinnamonitrile
benzeneacetonitrile, alpha-(diphenylmethylene)-
2,3,3-trifenylakrylonitril [czech]
einecs 228-610-4
benzeneacetic acid, alpha-(diphenylmethylene)-
ai3-63069
7136-23-4
acrylonitrile,3,3-triphenyl-
benzeneacetonitrile, .alpha.-(diphenylmethylene)-
mls002608486 ,
2,3-triphenylacrylonitrile
.alpha.,.beta.-diphenylcinnamonitrile
triphenylcyanoethylene
acrylonitrile, triphenyl-
.alpha.,.beta.-triphenylacrylonitrile
benzeneacetic acid, .alpha.-(diphenylmethylene)-
nsc42900
triphenylacrylonitrile
6304-33-2
wln: ncyr&uyr&r
nsc-42900
2,3, 3-triphenylacrylonitrile
.alpha.,.beta., .beta.-triphenylacrylonitrile
acrylonitrile, 2,3,3-triphenyl-
2,3,3-triphenylacrylonitrile
2,3,3-triphenylprop-2-enenitrile
chebi:34217 ,
2,3,3-triphenyl-acrylonitrile
CHEMBL305168
smr001527234
A834182
2,3,3-triphenyl-2-propenenitrile
HMS3078C14
2,3,3-trifenylakrylonitril
FT-0636085
SCHEMBL1343904
AKOS025117037
DTXSID60212329
OPACMJHTQWVSKW-UHFFFAOYSA-N
Q27115912
CS-0454461
PD180111
alpha-(diphenylmethylene)benzeneacetonitrile
33Q5RZG6CP
acrylonitrile, 2,2,3-triphenyl-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686978
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
DNA polymerase eta isoform 1Homo sapiens (human)Potency50.11870.100028.9256213.3130AID588591
Guanine nucleotide-binding protein GHomo sapiens (human)Potency35.48131.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID102623Percent of inhibitory activity against proliferation of MCF-7 cells in presence of 10e-6 M concentration of [3H]estradiol (E2).1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID103600Agonistic activity in MCF-7 cell proliferation.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID102435Effective dose for [3H]- estradiol against proliferation of MCF-7 cells1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID164970The percent stimulation or inhibition of protein kinase C III activity was determined for phosphatidylserine (PS) and diolein(PS+DO) in the presence of [Ca2+]1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID42279Inhibition of proliferation of BT-20 cells in presence of 10e-5 TPE concentration; nm = not measuable1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID102603Inhibition of proliferation of MCF-7 cells versus 0.1 nM [3H]- estradiol; nm = not measuable1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID71133Relative binding affinity against estrogen receptor in calf uterus cytosol using [3H]E2 as radioligand, incubated at 2 hours at 0 degree Centigrade.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID71134Relative binding affinity against estrogen receptor in calf uterus cytosol using [3H]E2 as radioligand, incubated at 5 hours at 25 degree Centigrade.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID103754Cytostatic activity against MCF-7 cell proliferation.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID164971Percent stimulation or inhibition of protein kinase C III activity for phosphatidylserine (PS) in the presence of [Ca2+].1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID102449Inhibition of proliferation of MCF-7 cells in presence of 10e-6 M concentration of [3H]- estradiol (E2); nm = not measuable1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID71132Relative binding affinity was measured on calf uterus estrogen receptor after 5 hr at 25C.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID42280Percent of inhibitory activity against proliferation of BT-20 cells in presence of TPE at 10e-5 M concentration.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID102768Percent of effective dose for [3H]estradiol against proliferation of MCF-7 cells.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID102624Percent of inhibitory activity versus 0.1 nm [3H]estradiol against proliferation of MCF-7 cells.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID164972Percent stimulation or inhibition of protein kinase C III activity for protamine sulfate in the presence of EGTA.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (30.00)18.7374
1990's1 (10.00)18.2507
2000's1 (10.00)29.6817
2010's4 (40.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]